Exosomal miR-17-5p, miR-146a-3p, and miR-223-3p Correlate with Radiologic Sequelae in Survivors of COVID-19-Related Acute Respiratory Distress Syndrome
Abstract
:1. Introduction
2. Results
2.1. Characteristics of the Study Population
2.2. Radiological Findings
2.3. miRNAs
3. Discussion
4. Materials and Methods
Statistical Analysis
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- WHO Coronavirus (COVID-19) Dashboard [Online Database]; World Health Organization: Geneva, Switzerland, 2021; Available online: https://covid19.who.int (accessed on 18 July 2023).
- Watson, O.J.; Barnsley, G.; Toor, J.; Hogan, A.B.; Winskill, P.; Ghani, A.C. Global impact of the first year of COVID-19 vaccination: A mathematical modelling study. Lancet Infect. Dis. 2022, 22, 1293–1302. [Google Scholar] [CrossRef]
- Huang, C.; Huang, L.; Wang, Y.; Li, X.; Ren, L.; Gu, X.; Kang, L.; Guo, L.; Liu, M.; Zhou, X.; et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet 2021, 397, 220–232. [Google Scholar] [CrossRef]
- Guler, S.A.; Ebner, L.; Aubry-Beigelman, C.; Bridevaux, P.-O.; Brutsche, M.; Clarenbach, C.; Garzoni, C.; Geiser, T.K.; Lenoir, A.; Mancinetti, M.; et al. Pulmonary function and radiological features 4 months after COVID-19: First results from the national prospective observational Swiss COVID-19 lung study. Eur. Respir. J. 2021, 57, 2003690. [Google Scholar] [CrossRef]
- Safont, B.; Tarraso, J.; Rodriguez-Borja, E.; Fernández-Fabrellas, E.; Sancho-Chust, J.N.; Molina, V.; Lopez-Ramirez, C.; Lope-Martinez, A.; Cabanes, L.; Andreu, A.L.; et al. Lung Function, Radiological Findings and Biomarkers of Fibrogenesis in a Cohort of COVID-19 Patients Six Months after Hospital Discharge. Arch. Bronconeumol. 2021, 58, 142–149. [Google Scholar] [CrossRef]
- Baratella, E.; Ruaro, B.; Marrocchio, C.; Starvaggi, N.; Salton, F.; Giudici, F.; Quaia, E.; Confalonieri, M.; Cova, M.A. Interstitial Lung Disease at High Resolution CT after SARS-CoV-2-Related Acute Respiratory Distress Syndrome according to Pulmonary Segmental Anatomy. J. Clin. Med. 2021, 10, 3985. [Google Scholar] [CrossRef]
- Lenoir, A.; Christe, A.; Ebner, L.; Beigelman-Aubry, C.; Bridevaux, P.-O.; Brutsche, M.; Clarenbach, C.; Erkosar, B.; Garzoni, C.; Geiser, T.; et al. Pulmonary Recovery 12 Months after Non-Severe and Severe COVID-19: The Prospective Swiss COVID-19 Lung Study. Respiration 2023, 102, 120–133. [Google Scholar] [CrossRef]
- Lage, S.L.; Amaral, E.P.; Hilligan, K.L.; Laidlaw, E.; Rupert, A.; Namasivayan, S.; Rocco, J.; Galindo, F.; Kellogg, A.; Kumar, P.; et al. Persistent Oxidative Stress and Inflammasome Activation in CD14highCD16− Monocytes from COVID-19 Patients. Front. Immunol. 2022, 12, 799558. [Google Scholar] [CrossRef]
- Wynn, T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008, 214, 199–210. [Google Scholar] [CrossRef]
- Saifi, M.A.; Bansod, S.; Godugu, C. COVID-19 and fibrosis: Mechanisms, clinical relevance, and future perspectives. Drug Discov. Today 2022, 27, 103345. [Google Scholar] [CrossRef]
- Arun, G.; Diermeier, S.D.; Spector, D.L. Therapeutic Targeting of Long Non-Coding RNAs in Cancer. Trends Mol. Med. 2018, 24, 257–277. [Google Scholar] [CrossRef]
- Esteller, M. Non-coding RNAs in human disease. Nat. Rev. Genet. 2011, 12, 861–874. [Google Scholar] [CrossRef]
- Farooqi, A.A.; Desai, N.N.; Qureshi, M.Z.; Librelotto, D.R.N.; Gasparri, M.L.; Bishayee, A.; Nabavi, S.M.; Curti, V.; Daglia, M. Exosome biogenesis, bioactivities and functions as new delivery systems of natural compounds. Biotechnol. Adv. 2018, 36, 328–334. [Google Scholar] [CrossRef]
- Regev-Rudzki, N.; Wilson, D.W.; Carvalho, T.G.; Sisquella, X.; Coleman, B.M.; Rug, M.; Bursac, D.; Angrisano, F.; Gee, M.; Hill, A.F.; et al. Cell-Cell Communication between Malaria-Infected Red Blood Cells via Exosome-like Vesicles. Cell 2013, 153, 1120–1133. [Google Scholar] [CrossRef]
- Gallo, A.; Tandon, M.; Alevizos, I.; Illei, G.G. The Majority of MicroRNAs Detectable in Serum and Saliva Is Concentrated in Exosomes. PLoS ONE 2012, 7, e30679. [Google Scholar] [CrossRef]
- Houshmandfar, S.; Saeedi-Boroujeni, A.; Rashno, M.; Khodadadi, A.; Mahmoudian-Sani, M.-R. miRNA-223 as a regulator of inflammation and NLRP3 inflammasome, the main fragments in the puzzle of immunopathogenesis of different inflammatory diseases and COVID-19. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2021, 394, 2187–2195. [Google Scholar] [CrossRef]
- Houshmandfar, S.; Khodadadi, A.; Mahmoudian-Sani, M.-R.; Nashibi, R.; Rashno, M. Comparing the expression of MiR-223-NLRP3-IL-1β axis and serum IL-1β levels in patients with severe COVID-19 and healthy individuals. Immunobiology 2023, 228, 152710. [Google Scholar] [CrossRef]
- García-Hidalgo, M.C.; González, J.; Benítez, I.D.; Carmona, P.; Santisteve, S.; Pérez-Pons, M.; Moncusí-Moix, A.; Gort-Paniello, C.; Rodríguez-Jara, F.; Molinero, M.; et al. Identification of circulating microRNA profiles associated with pulmonary function and radiologic features in survivors of SARS-CoV-2-induced ARDS. Emerg. Microbes Infect. 2022, 11, 1537–1549. [Google Scholar] [CrossRef]
- Wu, L.; Zhang, G.; Guo, C.; Zhao, X.; Shen, D.; Yang, N. MiR-128-3p mediates TNF-α-induced inflammatory responses by regulating Sirt1 expression in bone marrow mesenchymal stem cells. Biochem. Biophys. Res. Commun. 2019, 521, 98–105. [Google Scholar] [CrossRef]
- Wallach, T.; Mossmann, Z.J.; Szczepek, M.; Wetzel, M.; Machado, R.; Raden, M.; Miladi, M.; Kleinau, G.; Krüger, C.; Dembny, P.; et al. MicroRNA-100-5p and microRNA-298-5p released from apoptotic cortical neurons are endogenous Toll-like receptor 7/8 ligands that contribute to neurodegeneration. Mol. Neurodegener. 2021, 16, 80. [Google Scholar] [CrossRef]
- Li, G.; Wang, B.; Ding, X.; Zhang, X.; Tang, J.; Lin, H. Plasma extracellular vesicle delivery of miR-210-3p by targeting ATG7 to promote sepsis-induced acute lung injury by regulating autophagy and activating inflammation. Exp. Mol. Med. 2021, 53, 1180–1191. [Google Scholar] [CrossRef]
- Ravaglia, C.; Doglioni, C.; Chilosi, M.; Piciucchi, S.; Dubini, A.; Rossi, G.; Pedica, F.; Puglisi, S.; Donati, L.; Tomassetti, S.; et al. Clinical, radiological and pathological findings in patients with persistent lung disease following SARS-CoV-2 infection. Eur. Respir. J. 2022, 60, 2102411. [Google Scholar] [CrossRef] [PubMed]
- Barnes, P.J. Immunology of asthma and chronic obstructive pulmonary disease. Nat. Rev. Immunol. 2008, 8, 183–192. [Google Scholar] [CrossRef] [PubMed]
- Farber, H.W.; Loscalzo, J. Pulmonary arterial hypertension. N. Engl. J. Med. 2004, 351, 1655–1665. [Google Scholar] [CrossRef] [PubMed]
- Selman, M.; King, T.E., Jr.; Pardo, A.; American Thoracic Society; European Respiratory Society; American College of Chest Physicians. Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy. Ann. Intern. Med. 2001, 134, 136–151. [Google Scholar] [CrossRef]
- Freeman, T.L.; Swartz, T.H. Targeting the NLRP3 Inflammasome in Severe COVID-19. Front. Immunol. 2020, 11, 1518. [Google Scholar] [CrossRef]
- Yang, Y.; Huang, G.; Xu, Q.; Zhao, G.; Jiang, J.; Li, Y.; Guo, Z. miR-146a-5p Attenuates Allergic Airway Inflammation by Inhibiting the NLRP3 Inflammasome Activation in Macrophages. Int. Arch. Allergy Immunol. 2022, 183, 919–930. [Google Scholar] [CrossRef]
- Taganov, K.D.; Boldin, M.P.; Chang, K.-J.; Baltimore, D. NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. USA 2006, 103, 12481–12486. [Google Scholar] [CrossRef]
- O’Connell, R.M.; Rao, D.S.; Baltimore, D. microRNA Regulation of Inflammatory Responses. Annu. Rev. Immunol. 2012, 30, 295–312. [Google Scholar] [CrossRef]
- Cheng, H.S.; Sivachandran, N.; Lau, A.; Boudreau, E.; Zhao, J.L.; Baltimore, D.; Delgado-Olguin, P.; Cybulsky, M.I.; Fish, J.E. MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways. EMBO Mol. Med. 2013, 5, 1017–1034. [Google Scholar] [CrossRef]
- Sheedy, F.J. Turning 21: Induction of miR-21 as a Key Switch in the Inflammatory Response. Front. Immunol. 2015, 6, 19. [Google Scholar] [CrossRef]
- Li, S.; Yue, Y.; Xu, W.; Xiong, S. MicroRNA-146a Represses Mycobacteria-Induced Inflammatory Response and Facilitates Bacterial Replication via Targeting IRAK-1 and TRAF-6. PLoS ONE 2013, 8, e81438. [Google Scholar] [CrossRef] [PubMed]
- Hou, J.; Wang, P.; Lin, L.; Liu, X.; Ma, F.; An, H.; Wang, Z.; Cao, X. MicroRNA-146a Feedback Inhibits RIG-I-Dependent Type I IFN Production in Macrophages by Targeting TRAF6, IRAK1, and IRAK2. J. Immunol. 2009, 183, 2150–2158. [Google Scholar] [CrossRef]
- Roganović, J. Downregulation of microRNA-146a in diabetes, obesity and hypertension may contribute to severe COVID-19. Med. Hypotheses 2020, 146, 110448. [Google Scholar] [CrossRef] [PubMed]
- Lambert, K.A.; Roff, A.N.; Panganiban, R.P.; Douglas, S.; Ishmael, F.T. MicroRNA-146a is induced by inflammatory stimuli in airway epithelial cells and augments the anti-inflammatory effects of glucocorticoids. PLoS ONE 2018, 13, e0205434. [Google Scholar] [CrossRef] [PubMed]
- Sabbatinelli, J.; Giuliani, A.; Matacchione, G.; Latini, S.; Laprovitera, N.; Pomponio, G.; Ferrarini, A.; Baroni, S.S.; Pavani, M.; Moretti, M.; et al. Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients. Mech. Ageing Dev. 2021, 193, 111413. [Google Scholar] [CrossRef]
- Pei, Z.; Cen, J.; Zhang, X.; Gong, C.; Sun, M.; Meng, W.; Mao, G.; Wan, J.; Hu, B.; He, X.; et al. MiR-146a-5p delivered by hucMSC extracellular vesicles modulates the inflammatory response to sulfur mustard-induced acute lung injury. Stem Cell Res. Ther. 2023, 14, 149. [Google Scholar] [CrossRef] [PubMed]
- Bauernfeind, F.; Rieger, A.; Schildberg, F.A.; Knolle, P.A.; Schmid-Burgk, J.L.; Hornung, V. NLRP3 Inflammasome Activity Is Negatively Controlled by miR-223. J. Immunol. 2012, 189, 4175–4181. [Google Scholar] [CrossRef]
- Johnnidis, J.B.; Harris, M.H.; Wheeler, R.T.; Stehling-Sun, S.; Lam, M.H.; Kirak, O.; Brummelkamp, T.R.; Fleming, M.D.; Camargo, F.D. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 2008, 451, 1125–1129. [Google Scholar] [CrossRef]
- Neudecker, V.; Brodsky, K.S.; Clambey, E.T.; Schmidt, E.P.; Packard, T.A.; Davenport, B.; Standiford, T.J.; Weng, T.; Fletcher, A.A.; Barthel, L.; et al. Neutrophil transfer of miR-223 to lung epithelial cells dampens acute lung injury in mice. Sci. Transl. Med. 2017, 9, eaah5360. [Google Scholar] [CrossRef]
- Roffel, M.P.; Bracke, K.R.; Heijink, I.H.; Maes, T. miR-223: A Key Regulator in the Innate Immune Response in Asthma and COPD. Front. Med. 2020, 7, 196. [Google Scholar] [CrossRef]
- Morales, L.; Oliveros, J.C.; Enjuanes, L.; Sola, I. Contribution of Host miRNA-223-3p to SARS-CoV-Induced Lung Inflammatory Pathology. mBio 2022, 13, e0313521. [Google Scholar] [CrossRef] [PubMed]
- Dakhlallah, D.; Batte, K.; Wang, Y.; Cantemir-Stone, C.Z.; Yan, P.; Nuovo, G.; Mikhail, A.; Hitchcock, C.L.; Wright, V.P.; Nana-Sinkam, S.P.; et al. Epigenetic Regulation of miR-17∼92 Contributes to the Pathogenesis of Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 2013, 187, 397–405. [Google Scholar] [CrossRef] [PubMed]
- Meder, B.; Backes, C.; Haas, J.; Leidinger, P.; Stähler, C.; Großmann, T.; Vogel, B.; Frese, K.; Giannitsis, E.; Katus, H.A.; et al. Influence of the Confounding Factors Age and Sex on MicroRNA Profiles from Peripheral Blood. Clin. Chem. 2014, 60, 1200–1208. [Google Scholar] [CrossRef]
- Heneghan, H.M.; Miller, N.; McAnena, O.J.; O’Brien, T.; Kerin, M.J. Differential miRNA Expression in Omental Adipose Tissue and in the Circulation of Obese Patients Identifies Novel Metabolic Biomarkers. J. Clin. Endocrinol. Metab. 2011, 96, E846–E850. [Google Scholar] [CrossRef]
- Vijayan, M.; Reddy, P.H. Non-Coding RNAs Based Molecular Links in Type 2 Diabetes, Ischemic Stroke, and Vascular Dementia. J. Alzheimer’s Dis. 2020, 75, 353–383. [Google Scholar] [CrossRef]
- Kevadiya, B.D.; Machhi, J.; Herskovitz, J.; Oleynikov, M.D.; Blomberg, W.R.; Bajwa, N.; Soni, D.; Das, S.; Hasan, M.; Patel, M.; et al. Diagnostics for SARS-CoV-2 infections. Nat. Mater. 2021, 20, 593–605. [Google Scholar] [CrossRef]
- ARDS Definition of Task Force; Ranieri, V.M.; Rubenfeld, G.D.; Thompson, B.T.; Ferguson, N.D.; Caldwell, E.; Fan, E.; Camporota, L.; Slutsky, A.S. Acute Respiratory Distress Syndrome: The Berlin Definition. JAMA 2012, 307, 2526–2533. [Google Scholar] [CrossRef]
- Antonio, G.E.; Wong, K.T.; Hui, D.S.C.; Wu, A.; Lee, N.; Yuen, E.H.Y.; Leung, C.B.; Rainer, T.H.; Cameron, P.; Chung, S.S.C.; et al. Thin-Section CT in Patients with Severe Acute Respiratory Syndrome Following Hospital Discharge: Preliminary Experience. Radiology 2003, 228, 810–815. [Google Scholar] [CrossRef]
- Wong, K.T.; Antonio, G.E.; Hui, D.S.; Ho, C.; Chan, P.N.; Ng, W.H.; Shing, K.K.; Wu, A.; Lee, N.; Yap, F.; et al. Severe acute respiratory syndrome: Thin-section computed tomography features, temporal changes, and clinicoradiologic correlation during the convalescent period. J. Comput. Assist. Tomogr. 2004, 28, 790–795. [Google Scholar] [CrossRef] [PubMed]
Total | Fibrotic-like Lesions (FL) | Pulmonary Opacities (PO) | Normal (N) | p | |
---|---|---|---|---|---|
N = 31 | N = 9 | N = 11 | N = 11 | ||
Age, years | 60 ± 6 | 61 ± 6 | 60 ± 6 | 58 ± 7 | 0.25 |
Male sex, % | 33 | 44 | 36 | 33 | 0.42 |
Height, cm | 170 ± 7 | 168 ± 9 | 171 ± 11 | 171 ± 7 | 0.55 |
BMI, Kg/m2 | 31.1 ± 6.6 | 31.7 ± 7.2 | 30.1 ± 5.7 | 30.7 ± 6.6 | 0.56 |
Current smokers, % | 7 | 0 | 0 | 18 | 0.21 |
Hypertension, % | 61 | 54 | 60 | 71 | 0.79 |
T2DM, % | 10 | 0 | 9 | 20 | 0.44 |
COPD, % | 10 | 12 | 16 | 0 | 0.41 |
Previous CV event, % | 4 | 14 | 0 | 0 | 0.25 |
Hospital length of stay, days | 18 ± 9 | 23 ± 10 | 18 ± 8 | 15 ± 6 | 0.13 |
Serum lymphocytes, mm3 | 791 ± 351 | 833 ± 377 | 692 ± 391 | 859 ± 297 | 0.51 |
CRP acute phase, mg/dL | 6.9 [4.0–12.0] | 7.5 [2.5–12.5] | 6.5 [4.2–16.8] | 6.1 [3.3–10.6] | 0.88 |
Ferritin acute phase, ng/mL | 950 [426–1300] | 804 [534–1579] | 1205 [674–1331] | 400 [359–1133] | 0.45 |
ETI, % | 6 | 11 | 0 | 9 | 0.52 |
NIV, % | 36 | 44 | 38 | 27 | 0.75 |
cPAP, % | 12 | 11 | 15 | 9 | 0.90 |
Time from discharge, days | 121 ± 39 | 118 ± 41 | 139 ± 43 | 105 ± 18 | 0.16 |
Dyspnea, % | 27 | 33 | 8 | 45 | 0.11 |
Asthenia, % | 6 | 11 | 0 | 9 | 0.51 |
Depression, % | 18 | 22 | 15 | 18 | 0.92 |
Peak oxygen consumption, mL/min/Kg | 18.4 ± 5 | 18.9 ± 4 | 18.4 ± 4 | 17.8 ± 5 | 0.80 |
CRP follow-up, mg/dL | 0.2 [0.1–0.3] | 0.1 [0.1–0.4] | 0.2 [0.1–0.5] | 0.2 [0.1–0.3] | 0.61 |
Ferritin follow-up, ng/mL | 108 [34–245] | 126 [42–215] | 138 [29–293] | 62 [26–214] | 0.43 |
Fibrotic-like Lesions (FL) | Pulmonary Opacities (PO) | Normal (N) | p (ANOVA) | |
---|---|---|---|---|
GGO, acute phase | 13.1 ± 4 | 9.8 ± 3 | 8.3 ± 3 | 0.02 |
GGO, Follow-up | 4.4 ± 1 | 3.8 ± 1 | 0.1 ± 1 | <0.01 |
Consolidations, acute phase | 2.9 ± 2 | 3.7 ± 2 | 4.2 ± 2 | 0.33 |
Consolidations, Follow-up | 0 | 1.2 ± 1 | 0.1 ± 1 | 0.21 |
Reticulations, acute phase | 0 | 0 | 0 | - |
Reticulations, Follow-up | 3.5 ± 1 | 0.6 ± 1 | 0.2 ± 1 | <0.01 |
Traction bronchiectasis, acute phase | 0 | 0 | 0 | - |
Traction bronchiectasis, follow-up | 1.9 ± 1 | 0 | 0 | <0.01 |
ID | mRNA Target |
---|---|
miR128-3p | TNF-alfa |
miR17-5p | NLRP3 * |
miR146a-5p | NLRP3 |
miR21-5p | HIF1-alfa/alfa-SMA/Collagene-1 |
miR223-3p | NLRP3 * |
miR100-5p | mTOR |
miR210-3p | ATG7 |
miR141-3p | NLRP4 |
miR106a-5p | IL-10/STAT3 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Curcio, R.; Poli, G.; Fabi, C.; Sugoni, C.; Pasticci, M.B.; Ferranti, R.; Rossi, M.; Folletti, I.; Sanesi, L.; Santoni, E.; et al. Exosomal miR-17-5p, miR-146a-3p, and miR-223-3p Correlate with Radiologic Sequelae in Survivors of COVID-19-Related Acute Respiratory Distress Syndrome. Int. J. Mol. Sci. 2023, 24, 13037. https://doi.org/10.3390/ijms241713037
Curcio R, Poli G, Fabi C, Sugoni C, Pasticci MB, Ferranti R, Rossi M, Folletti I, Sanesi L, Santoni E, et al. Exosomal miR-17-5p, miR-146a-3p, and miR-223-3p Correlate with Radiologic Sequelae in Survivors of COVID-19-Related Acute Respiratory Distress Syndrome. International Journal of Molecular Sciences. 2023; 24(17):13037. https://doi.org/10.3390/ijms241713037
Chicago/Turabian StyleCurcio, Rosa, Giulia Poli, Consuelo Fabi, Chiara Sugoni, Maria Bruna Pasticci, Roberto Ferranti, Monica Rossi, Ilenia Folletti, Leandro Sanesi, Edoardo Santoni, and et al. 2023. "Exosomal miR-17-5p, miR-146a-3p, and miR-223-3p Correlate with Radiologic Sequelae in Survivors of COVID-19-Related Acute Respiratory Distress Syndrome" International Journal of Molecular Sciences 24, no. 17: 13037. https://doi.org/10.3390/ijms241713037